Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

NCT02477631 ·Status: COMPLETED ·Phase: PHASE2

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP

NCT00733811 ·Status: COMPLETED ·Phase: PHASE4

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

NCT00379483 ·Status: COMPLETED ·Phase: PHASE2

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266 ·Status: COMPLETED ·Phase: PHASE2

A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome

NCT00095264 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

NCT01459718 ·Status: TERMINATED ·Phase: PHASE2

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

NCT03637556 ·Status: COMPLETED ·Phase: PHASE2

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

NCT00901199 ·Status: COMPLETED ·Phase: PHASE2

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

NCT00560820 ·Status: COMPLETED ·Phase: PHASE1

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

NCT00061763 ·Status: COMPLETED ·Phase: PHASE2

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet

NCT02993224 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

NCT00000595 ·Status: COMPLETED ·Phase: PHASE2

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

NCT01948817 ·Status: WITHDRAWN ·Phase: PHASE2

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

NCT00103753 ·Status: UNKNOWN ·Phase: PHASE4

A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects

NCT02497924 ·Status: COMPLETED ·Phase: PHASE1

Post Hematopoietic Stem Cell Transplantation

NCT01610297 ·Status: COMPLETED ·Phase: PHASE4

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

NCT01892644 ·Status: WITHDRAWN ·Phase: PHASE2

Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms

NCT02823184 ·Status: COMPLETED

Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major

NCT00800761 ·Status: COMPLETED ·Phase: PHASE4

Treatment of Iron Overload Requiring Chelation Therapy

NCT01927913 ·Status: WITHDRAWN ·Phase: PHASE2

Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia

NCT00069862 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

NCT00057031 ·Status: UNKNOWN ·Phase: PHASE2

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00117507 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia

NCT01709838 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

NCT00395629 ·Status: COMPLETED ·Phase: PHASE1/PHASE2